Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
We break down Nobl SDY fees, showing which charges eat into profits and how to minimize them through smarter selection and timing of trades.
20,285 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Tech’s latest earnings show Big Tech leaning into AI infrastructure, pushing capital spending higher as data centers ...
May 2026 hands investors a surprise: a big jump in M2 money supply could rekindle inflation pressures. Markets weigh ...
AMD and Marvell released quarterly results centered on AI infrastructure, highlighting different strategic bets in da...
A seven-year high in regional bank M&A signals bigger players aiming for scale and efficiency. This guide breaks down...
Microsoft leads a renewed sector rotation as AI momentum and stable cloud revenue lift its outlook, while Intel stumb...
AeroVironment stock climbed today after a major government contract announcement. This article breaks down what happe...
Insider moves can reveal more than a single trade. This article breaks down the photonics director sells 1,511, expla...
When the S&P 500 rebalances, a short-lived selling ripple hits stocks leaving the index. This article explains how to...
A forecasting model linked to Sam Altman and ChatGPT projects a Meta surge by 2026, driven by AI driven ads, WhatsApp...
XRP surged above key resistance as volume inflows and ETF demand point to renewed institutional interest. Regulators ...
A Chinese AI model is reported to rival US leaders in performance, sparking a reassessment of investments in data cen...